|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,997.60 INR | -1.81% |
|
+3.25% | -1.85% |
| 02/02 | Glenmark Pharmaceuticals Posts Higher Profit in Fiscal Q3 | MT |
| 02/02 | Glenmark Pharmaceuticals Limited, Q3 2026 Earnings Call, Feb 02, 2026 |
| Capitalization | 56TCr 622.4Cr 524.44Cr 478.34Cr 456.67Cr 847.71Cr 880.76Cr 5.56TCr 2.21TCr 27TCr 2.33TCr 2.29TCr 95TCr | P/E ratio 2026 * |
31.5x | P/E ratio 2027 * | 24.4x |
|---|---|---|---|---|---|
| Enterprise value | 52TCr 579.02Cr 487.88Cr 444.99Cr 424.84Cr 788.62Cr 819.37Cr 5.18TCr 2.05TCr 25TCr 2.17TCr 2.13TCr 89TCr | EV / Sales 2026 * |
3.4x | EV / Sales 2027 * | 3.18x |
| Free-Float |
49.4% | Yield 2026 * |
0.14% | Yield 2027 * | 0.16% |
Last Transcript: Glenmark Pharmaceuticals Limited
| 1 day | -1.81% | ||
| 1 week | +3.25% | ||
| Current month | -0.91% | ||
| 1 month | -0.53% | ||
| 3 months | +6.22% | ||
| 6 months | -1.56% | ||
| Current year | -1.85% |
| 1 week | 1,941.4 |  | 2,047.9 |
| 1 month | 1,842 | | 2,047.9 |
| Current year | 1,842 | | 2,147.5 |
| 1 year | 1,275.5 | | 2,284.8 |
| 3 years | 414.25 | | 2,284.8 |
| 5 years | 348.5 | | 2,284.8 |
| 10 years | 161.65 | | 2,284.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2000 | |
Anurag Mantri
DFI | Director of Finance/CFO | 54 | 27/05/2025 |
Indrajit Bose
PSD | President | - | 15/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Cherylann Pinto
BRD | Director/Board Member | 58 | - |
| Chairman | 56 | 12/05/2011 | |
| Director/Board Member | 85 | 14/08/2009 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.81% | +3.25% | +41.55% | +372.69% | 622.4Cr | |
| -1.01% | +0.14% | -2.80% | +67.20% | 4.5TCr | |
| +7.23% | +13.28% | +30.34% | +158.17% | 3.66TCr | |
| +0.11% | +0.11% | -9.55% | +30.29% | 1.19TCr | |
| -1.76% | +1.86% | -4.05% | +91.90% | 1.01TCr | |
| +2.69% | +7.00% | +196.89% | +928.85% | 862.42Cr | |
| -0.84% | +1.73% | +43.73% | +121.70% | 849.65Cr | |
| -1.21% | +7.31% | +71.26% | +33.63% | 819.43Cr | |
| +1.26% | +2.09% | +62.23% | -10.40% | 779.7Cr | |
| -0.51% | +1.92% | +9.24% | +47.26% | 667.83Cr | |
| Average | +0.42% | +2.58% | +43.89% | +184.13% | 1.49TCr | |
| Weighted average by Cap. | +1.36% | +3.93% | +28.69% | +146.94% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15TCr 170.27Cr 143.47Cr 130.86Cr 124.93Cr 231.9Cr 240.95Cr 1.52TCr 604.21Cr 7.45TCr 638.54Cr 625.41Cr 26TCr | 16TCr 179.54Cr 151.28Cr 137.98Cr 131.73Cr 244.53Cr 254.07Cr 1.6TCr 637.12Cr 7.85TCr 673.31Cr 659.47Cr 27TCr |
| Net income | 1.96TCr 22Cr 18Cr 17Cr 16Cr 29Cr 31Cr 193.33Cr 77Cr 945.97Cr 81Cr 79Cr 3.31TCr | 2.31TCr 25Cr 21Cr 20Cr 19Cr 35Cr 36Cr 227.79Cr 90Cr 1.11TCr 96Cr 94Cr 3.9TCr |
| Net Debt | -3.93TCr -43Cr -37Cr -33Cr -32Cr -59Cr -61Cr -387.81Cr -153.95Cr -1.9TCr -162.7Cr -159.35Cr -6.63TCr | -4.7TCr -52Cr -44Cr -40Cr -38Cr -71Cr -73Cr -464.14Cr -184.25Cr -2.27TCr -194.72Cr -190.72Cr -7.94TCr |
Employees
15,800
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/26/13 | 1,997.60 ₹ | -1.81% | 8,65,050 |
| 12/26/12 | 2,034.50 ₹ | +0.96% | 3,39,344 |
| 11/26/11 | 2,015.20 ₹ | +2.92% | 5,48,543 |
| 10/26/10 | 1,958.00 ₹ | -0.83% | 2,78,908 |
| 09/26/09 | 1,974.40 ₹ | +2.05% | 3,99,133 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
1,997.60INR
Average target price
2,192.67INR
Spread / Average Target
+9.77%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GLENMARK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition